A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tumors. Methods The study consisted of 2 dose levels of creni...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Doi, Toshihiko, Tajimi, Masaomi, Mori, Joji, Asou, Hiroya, Inoue, Koichi, Benhadji, Karim A., Naito, Yoichi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2020
Témata:
Phase I Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7960611/
https://ncbi.nlm.nih.gov/pubmed/32939607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01001-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky